Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) CEO Jeremy Bender sold 10,681 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the sale, the chief executive officer now owns 98,932 shares in the company, valued at $1,385,048. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Day One Biopharmaceuticals Stock Up 1.2 %
Shares of DAWN opened at $14.09 on Tuesday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The stock has a market capitalization of $1.23 billion, a P/E ratio of -5.61 and a beta of -1.51. The company has a 50 day moving average of $14.07 and a 200-day moving average of $14.79.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.29 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Wall Street Analyst Weigh In
Several research firms have weighed in on DAWN. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reissued an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.71.
Check Out Our Latest Stock Analysis on DAWN
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Recommended Stories
- Five stocks we like better than Day One Biopharmaceuticals
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- 3 Tickers Leading a Meme Stock Revival
- 2 Option Strategies to Maximize Profits in a Bear Market
- How Can Investors Benefit From After-Hours Trading
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.